
Vertex Pharmaceuticals statistics
$538.60−0.74%Close 13 Nov 2026
Valuation and share-price figures are struck on the latest close (13 Nov 2026); the others are read from the company's reports. A figure that cannot be worked out, such as a P/E after a loss, is left out.
Valuation
| Enterprise value | $136.7B |
|---|
| EV / EBITDA | 30.11 |
|---|
| EV / sales | 10.56 |
|---|
Share price
| Latest close | $538.60 |
|---|
| Day's change | −0.7% |
|---|
| 52-week high | $568.67 |
|---|
| 52-week low | $412.27 |
|---|
| From 52-week high | −5.3% |
|---|
| Return · 1 month | +7.8% |
|---|
| Return · 3 months | −0.3% |
|---|
| Return · year to date | +18.8% |
|---|
| Return · 1 year | +24.0% |
|---|
| Beta · 1 year against the S&P 500 | 0.43 |
|---|
| 50-day average | $522.37 |
|---|
| 200-day average | $483.34 |
|---|
| RSI 14 | 52.8 |
|---|
| Average volume · 20 sessions | 1.5M |
|---|
Margins and returns
For fiscal 2025, as filed.
| Gross margin | 86.2% |
|---|
| Operating margin | 34.8% |
|---|
| Net margin | 32.9% |
|---|
| Free cash flow margin | 26.6% |
|---|
| Return on equity | 22.5% |
|---|
| Return on assets | 14.8% |
|---|
| Return on invested capital | 25.1% |
|---|
| Return on capital employed | 20.5% |
|---|
| Stock-based compensation / revenue | 5.7% |
|---|
Financial position
At the end of fiscal 2025.
| Cash and equivalents | $5.08B |
|---|
| Total debt | $1.92B |
|---|
| Net debt | −$4.68B |
|---|
| Current ratio | 2.90 |
|---|
| Debt / equity | 0.10 |
|---|
| Net debt / EBITDA | −1.07 |
|---|
| Interest coverage | 313.78 |
|---|
Shares and dividends
For fiscal 2025, as filed.
| Diluted shares | 258M |
|---|
| Net share repurchases | $1.96B |
|---|
Taxes
For fiscal 2025, as filed.
| Income tax expense | $690.0M |
|---|
| Effective tax rate | 14.9% |
|---|
VRTX in the terminal
Valuation against the company's own history, a cash-flow valuation, peers, charts and alerts.